InMed holder buys 91K shares around $1.29

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. (INM) reported that private investment funds managed by ADAR1 Capital Management, LLC, a ten percent owner, made open-market purchases of a total of 91,101 common shares on September 14–16, 2026, at weighted average prices around $1.29 per share.

The shares are held by ADAR1-managed funds and may be deemed indirectly beneficially owned by ADAR1 Capital Management, LLC and Daniel Schneeberger, who each disclaim beneficial ownership except to the extent of any pecuniary interest. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Buyer: 91,101 shares

Net Buy 3 txns

Insider ADAR1 Capital Management, LLC, Schneeberger Daniel

Role 10% Owner | 10% Owner

Bought 91,101 shs ($118K)

Type	Security	Shares	Price	Value
Purchase	Common Shares F3, F4, F5	8,340	$1.289	$11K
Purchase	Common Shares F2, F4, F5	54,256	$1.2984	$70K
Purchase	Common Shares F1, F4, F5	28,505	$1.2938	$37K

Holdings After Transaction: Common Shares — 892,101 shares (Indirect, See Footnote)

Footnotes (5)

1. F1. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2900 to $1.3100, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
2. F2. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2800 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
3. F3. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2600 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
4. F4. The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
5. F5. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Key Figures

Total shares purchased: 91,101 shares September 14, 2026 purchase: 28,505 shares at $1.2938 per share September 15, 2026 purchase: 54,256 shares at $1.2984 per share +2 more

5 metrics

Total shares purchased 91,101 shares Aggregate open-market purchases by ADAR1-managed funds on September 14–16, 2026

September 14, 2026 purchase 28,505 shares at $1.2938 per share Common Shares, weighted average price with individual trades from $1.29 to $1.31

September 15, 2026 purchase 54,256 shares at $1.2984 per share Common Shares, weighted average price with individual trades from $1.28 to $1.30

September 16, 2026 purchase 8,340 shares at $1.2890 per share Common Shares, weighted average price with individual trades from $1.26 to $1.30

Net buy direction 91,101 shares net purchased All reported transactions are open-market purchases of Common Shares

Key Terms

weighted average price, indirectly beneficially owned, pecuniary interest, Section 16 of the Securities Exchange Act of 1934, +1 more

5 terms

weighted average price financial

"The reported price is a weighted average price. These shares were purchased"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

indirectly beneficially owned financial

"may be deemed to be indirectly beneficially owned by (i) ADAR1"

pecuniary interest financial

"disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest"

Section 16 of the Securities Exchange Act of 1934 regulatory

"For purposes of Section 16 of the Securities Exchange Act of 1934, as amended"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

ten percent owner regulatory

"each listed as a ten percent owner of InMed Pharmaceuticals Inc."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions were reported for INM in this Form 4?

Private investment funds managed by ADAR1 Capital Management, LLC reported open-market purchases of a total of 91,101 InMed common shares on September 14–16, 2026 at weighted average prices of about $1.29 per share.

Who are the reporting persons in this INM Form 4 filing?

The reporting persons are ADAR1 Capital Management, LLC and Daniel Schneeberger, each listed as a ten percent owner of InMed Pharmaceuticals Inc. The reported securities are owned directly by private investment funds managed by ADAR1.

What were the individual INM share purchases disclosed by ADAR1-managed funds?

The filing reports purchases of 28,505 shares at $1.2938 on September 14, 54,256 shares at $1.2984 on September 15, and 8,340 shares at $1.2890 on September 16, 2026. Each price is a weighted average across multiple trades in a narrow range.

At what price range were the INM shares bought according to the Form 4 footnotes?

Footnotes state the INM shares were purchased in multiple transactions at prices ranging from $1.26 to $1.31 per share, depending on the day, with each reported transaction price being a weighted average of those individual trades.

Are the INM shares in this Form 4 held directly by the reporting persons?

No. The shares are held directly by private investment funds managed by ADAR1. They may be deemed indirectly beneficially owned by ADAR1 Capital Management, LLC and Daniel Schneeberger, who each disclaim beneficial ownership except for any pecuniary interest.

Was a Rule 10b5-1 trading plan used for these INM insider purchases?

The document-level Rule 10b5-1 checkbox is not checked, so no Rule 10b5-1 trading plan is reported for these InMed Pharmaceuticals Inc. share purchases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 06:59 PM Accepted by SEC EDGAR 09/16/2026 - 06:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ADAR1 Capital Management, LLC

(Last) (First) (Middle)

3503 WILD CHERRY DRIVE

BUILDING 9

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ INM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/14/2026		P		28,505	A	$1.2938(1)	829,505	I	See Footnote(4)(5)
Common Shares	09/15/2026		P		54,256	A	$1.2984(2)	883,761	I	See Footnote(4)(5)
Common Shares	09/16/2026		P		8,340	A	$1.289(3)	892,101	I	See Footnote(4)(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

ADAR1 Capital Management, LLC

(Last) (First) (Middle)

3503 WILD CHERRY DRIVE

BUILDING 9

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Schneeberger Daniel

(Last) (First) (Middle)

3503 WILD CHERRY DRIVE

BUILDING 9

(Street)

AUSTIN TEXAS 78738

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2900 to $1.3100, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

2. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2800 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

3. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2600 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

4. The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

5. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

	ADAR1 Capital Management, LLC By: Daniel Schneeberger, Manager /s/ Daniel Schneeberger	09/16/2026
	/s/ Daniel Schneeberger	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)